What does the neurotech startup landscape look like today?
In our neurotechnology market deck, you will find everything you need to understand the market
SUMMARY
The neurotech startup landscape today is entering a real commercialization cycle: implanted BCIs are finally producing useful human results, but the first scalable businesses are emerging faster in neuromodulation, neural sensing and narrowly defined restorative devices.
Funding is booming at the top rather than across the whole market. Neurofounders tracked about $2.64 billion across 81 financing events in the first half of 2026, yet roughly three-quarters of disclosed capital came from only 13 rounds of at least $50 million.
BCI progress is no longer mainly a laboratory story. Neuralink, Synchron, Precision Neuroscience, Paradromics and newer entrants now have meaningful human experience, but the next test is much harder: long-term reliability, repeatable implantation and economics that work beyond tiny clinical cohorts.
The hardware race is splitting rather than converging. Neuralink favors bandwidth, Synchron favors procedural simplicity, Precision and ABILITY sit on the cortical surface, and Paradromics goes deeper for high-resolution signals. Different applications may end up producing different winners.
The companies closest to real revenue are mostly not the ones generating the biggest headlines. Science Corporation, Flow Neuroscience, Cala Health, Epitel and Precision already have approved, cleared or commercially deployable products while most general-purpose implanted BCIs remain investigational.
Neuromodulation currently looks like the cleaner business. It can sell a measurable therapeutic outcome through regulatory and reimbursement pathways that already exist, while BCI companies still have to prove both the interface and the market around it.
Vision restoration may be an unusually strong early neural-interface wedge because the clinical value is easy to understand and measure. Science Corporation’s PRIMA has already crossed into European commercial launch, putting it further down the commercialization path than most motor BCIs.
Consumer neurotech remains much less proven than the funding headlines suggest. Better EEG hardware can now disappear into headphones and other familiar devices, but no neural metric has yet become a daily consumer habit on the scale of steps, sleep or heart rate.
AI is increasing the value of neural hardware, especially by adapting decoders to noisy and changing biological signals, but it does not remove the physical bottlenecks. Electrode stability, surgery, wireless links, batteries and clinical evidence still set hard limits.
The competitive map is also becoming more international. The US still has the deepest frontier-BCI capital pool, while China is building a broader ecosystem around startups, hospitals, manufacturing, standards and early reimbursement experiments. The near-term winners are still likely to be companies solving one expensive neurological problem very well before trying to build general-purpose neural computing.
What actually counts as a neurotech startup today?
Today, a neurotech startup is best understood as a company whose core product directly reads, measures, stimulates or interfaces with the nervous system.
That definition gives us a much cleaner market than simply grouping every company that mentions the brain. It includes implanted brain-computer interfaces such as Neuralink, Synchron, Precision Neuroscience and Paradromics; neuromodulation companies such as Cala Health, Flow Neuroscience and Cognito Therapeutics; neural-monitoring companies such as Epitel; and consumer-facing companies such as Neurable and BrainCo.
We would leave ordinary mental-health apps, conventional neurological drugs and generic AI diagnostics outside the category unless the product actually interacts with neural signals or neural circuits.
The companies inside that definition are still building very different businesses. Neuralink is effectively trying to create a new computing interface. Flow Neuroscience sells a prescription treatment for depression. Epitel sells wireless EEG technology to healthcare providers. Science Corporation is starting to commercialize a retinal implant that restores some central vision.
They share neuroscience, but their customers, regulatory paths, capital needs and timelines are completely different. Talking about “the neurotech market” without separating those models hides more than it explains.
Is neurotech funding really booming right now?
Yes, neurotech funding is running hot right now, although the money is heavily concentrated in a relatively small group of companies.
Neurofounders’ updated H1 2026 review tracked roughly $2.64 billion across 81 financing events among 363 companies on its startup map. Only around 22% of those companies raised money. Nearly four out of five did not.
The distribution is even more revealing. The median round was around $7.9 million, while just 13 rounds of at least $50 million accounted for roughly three-quarters of disclosed capital. Seven rounds exceeded $100 million. This is a booming financing environment at the top, not an easy fundraising market for every neurotech founder.
The type of neurotech receiving money also tells us something. Neuromodulation attracted about $791 million, slightly more than the roughly $690 million going into BCI. Consumer neurotech reached about $357 million, although BrainCo and Temple accounted for roughly 95% of that category. BCI funding was similarly top-heavy, with Science Corporation and Merge Labs representing around 70% of first-half capital.
Funding stayed active after that period too. Neurofounders subsequently tracked roughly another $195 million in the following month, including a $26 million Series B for Epitel.
Investors are clearly paying much more attention to neurotech these days. They are also becoming selective about where they put serious money.
| Neurotech segment | Approx. H1 2026 funding | What we see |
|---|---|---|
| Neuromodulation | $791M | Large and relatively diversified |
| BCI | $690M | Huge rounds, concentrated among a few companies |
| Tools and infrastructure | $625M | Heavily inflated by one very large round |
| Consumer neurotech | $357M | Almost all the capital went to two companies |
| Neuroimaging | $125M | Smaller but more evenly spread |
| Diagnostics and assessment | $48M | Still a modest venture category |
This market map, featured in our neurotechnology market deck, highlights top companies and startups in the neurotechnology market
Are brain-computer interfaces finally working outside the lab?
Yes, implanted brain-computer interfaces are now being used by real patients for useful everyday tasks, which is a meaningful break from the previous decade of mostly small research demonstrations.
Neuralink gave the clearest evidence when it reported 21 participants across its clinical programs earlier in 2026, up from 12 several months earlier and only three at the end of 2024. Participants have used the implant to control computers, play games, create designs, study and operate assistive robotic hardware. One participant reached more than 10 bits per second of cursor-control performance, while another was reported by Neuralink to use the system for as much as 17 hours in one day.
The progress now extends well beyond Neuralink. Precision Neuroscience says its Layer 7 cortical interface has been placed in more than 95 clinical-study patients. Paradromics recently completed the first long-term implantation of its Connexus system in a patient with severe motor impairment. ABILITY Neurotech has also entered first-in-human testing, recording neural signals during brain surgery before a planned chronic implantation study.
The scale is still tiny compared with ordinary medical devices. We are talking about dozens or, for some temporary interfaces, around one hundred people. Long-term reliability remains uncertain for several platforms.
Even so, the old question of whether modern BCIs can produce useful computer control from human neural activity is basically settled. They can. Now comes the harder part: doing it safely, reliably and cheaply enough for thousands of patients.
Is Neuralink actually winning the BCI race?
Neuralink is currently leading the general-purpose implanted BCI race, especially in capital, clinical ambition and product breadth.
Its $650 million Series E brought total disclosed funding above $1 billion and gave Neuralink financial resources that most BCI startups cannot match. The company is simultaneously developing computer control, robotic-arm control, speech interfaces and visual prosthetics, while running clinical programs across several countries.
Neuralink has another advantage that gets less attention: it has built much of the stack itself. The company develops the implant, electrode threads, surgical robot, neural-decoding software and supporting infrastructure. More implants therefore feed directly back into engineering. The thread-retraction problem observed in its first participant, for example, led to changes in surgical technique for later procedures.
That creates a pretty powerful learning loop. Clinical volume gives Neuralink information about anatomy, electrode placement, signal stability, user behavior and surgery that a company with occasional human procedures cannot accumulate as quickly.
Still, the race is not finished. Neuralink's Telepathy system remains investigational, while Science Corporation has already reached commercial launch in Europe with PRIMA and Precision has an FDA-cleared component of its interface. Synchron is deliberately choosing a much easier surgical route.
Our view today is straightforward: Neuralink is ahead in the race to build the broadest implanted neural-computing platform. Whether that becomes the first large commercial BCI business remains open.
If you want more recent data on this point, please see our latest neurotechnology market report.
As this chart shows, and as featured in our neurotechnology market deck, search interest in neurotechnology has been climbing steadily
Can Synchron win by avoiding open-brain surgery?
Synchron could build a major BCI business with lower neural bandwidth than Neuralink because its biggest advantage is the way the device reaches the brain.
Synchron's Stentrode is delivered through the jugular vein and positioned inside a blood vessel next to the motor cortex. Its first-generation system uses 16 electrodes. Neuralink's N1 uses 1,024 electrodes placed directly into brain tissue through 64 flexible threads.
For pure signal collection, Neuralink has the more powerful architecture. Synchron is making a different bet: perhaps a patient who wants to send messages, browse an iPad or control basic software does not need 1,024 electrodes.
Ten patients with paralysis had received Stentrode implants by the company's $200 million Series D. Synchron has demonstrated integration with Apple devices through a BCI-specific human-interface protocol, letting users interact with systems including the iPhone, iPad and Vision Pro without touch, voice or eye tracking.
The company has also opened new clinical studies in Canada, Australia and the US as it works toward a larger commercial program. That expansion tells us more about Synchron's strategy than another cursor-speed demonstration would. It is trying to turn BCI implantation into something hospitals can eventually perform through a familiar catheter procedure.
The trade-off will become painful if future BCI applications require very rich neural information. Natural speech, dexterous movement and more complex control could favor interfaces with hundreds or thousands of high-quality channels.
For the first commercial paralysis product, though, Synchron's lower-bandwidth approach may prove commercially smarter than it initially looks.
Which BCI design looks strongest right now?
No single BCI design looks clearly superior today because the leading companies are optimizing for different things: signal quality, surgical risk, electrode density, reversibility and long-term stability.
Precision Neuroscience has pushed hardest toward the brain's surface. Its Layer 7 array contains 1,024 electrodes on a thin film that sits on the cortex rather than penetrating deeply into it. The FDA has cleared the interface for temporary recording, monitoring and stimulation for up to 30 days, and Precision now reports more than 95 clinical-study patients across over 15 hospital partners.
Paradromics goes deeper. Its Connexus module uses 421 penetrating microelectrodes designed to capture high-resolution neural activity, with speech restoration as an early target. The company recently moved from short intraoperative testing to its first long-term human implantation.
ABILITY Neurotech is developing another surface approach. Its system uses high-density ECoG and an optical data link designed to transmit large amounts of neural information wirelessly through intact skin. Its first human procedure has now happened in Munich, while a chronic ALS study is planned next.
Synchron sits at the less invasive end by recording through a blood vessel. Neuralink accepts a more complicated implantation procedure to place flexible electrodes directly in brain tissue.
The winning architecture may simply depend on the job. Sending a click command, decoding speech and restoring sensory information place very different demands on the interface.
| Company | Main approach | Electrode count / configuration | Main bet |
|---|---|---|---|
| Neuralink | Intracortical flexible threads | 1,024 electrodes | High bandwidth with robotic implantation |
| Synchron | Endovascular interface | 16 electrodes | Simpler implantation through blood vessels |
| Precision Neuroscience | Cortical-surface array | 1,024 electrodes per array | Dense recording without penetrating the cortex |
| Paradromics | Penetrating microelectrode array | 421 electrodes per module | High-resolution speech and communication decoding |
| ABILITY Neurotech | Cortical-surface ECoG | High-density surface array | High-bandwidth wireless transmission with less penetration |
If you want more recent data on this point, please see our latest neurotechnology market report.
This chart, featured in our neurotechnology market deck, shows annual VC investment in neurotechnology startups
Which neurotech startups are closest to real revenue today?
The neurotech companies closest to real commercial scale today are mostly focused medical-device businesses rather than general-purpose brain-computer platforms.
Science Corporation has now crossed one of the clearest commercial thresholds in the field. Its PRIMA retinal implant received European approval and the company has started its commercial launch, initially targeting Germany. PRIMA is therefore considerably further along commercially than the better-known motor BCIs.
Flow Neuroscience has full FDA premarket approval for its FL-100 home brain-stimulation device for adults with moderate-to-severe major depressive disorder. Cala Health already sells prescription wearable neuromodulation for essential tremor and Parkinson's-related tremor, with Medicare coverage available for qualifying essential-tremor patients.
Epitel gives us another useful example from neural sensing. The company recently raised $26 million to expand REMI, its FDA-cleared wireless EEG system. The money is going toward sales, provider adoption and commercial deployment rather than funding the first human experiment.
Precision also has something it can sell now. Its FDA clearance allows Layer 7 to be used for temporary cortical recording and stimulation, even while the company's fully implanted BCI remains under development.
The maturity gap inside neurotech is pretty stark. Some startups are trying to prove that an implant works in one or two people. Others are already dealing with manufacturing, hospital adoption, prescriptions, reimbursement and sales teams.
| Company | Product | Where it stands commercially |
|---|---|---|
| Science Corporation | PRIMA retinal prosthesis | Approved in Europe; commercial launch underway |
| Flow Neuroscience | FL-100 depression stimulation | FDA PMA approved; commercial distribution allowed |
| Cala Health | Cala kIQ | FDA cleared; reimbursement available for eligible patients |
| Epitel | REMI wireless EEG | FDA cleared; raising growth capital for commercial expansion |
| Precision Neuroscience | Layer 7 | FDA cleared for temporary cortical recording and stimulation |
| Neuralink / Paradromics | Implanted motor and communication BCIs | Still investigational |
Could restoring sight become neurotech's first big BCI business?
Vision restoration has suddenly become one of the most credible early BCI businesses because Science Corporation has moved PRIMA from clinical trials into commercial deployment.
PRIMA is a tiny subretinal implant designed for people who have lost central vision because of geographic atrophy from age-related macular degeneration. A camera mounted on specialized glasses captures the scene and sends infrared information to the implant, which electrically stimulates surviving retinal cells.
The pivotal European study enrolled 38 patients. Results published in the New England Journal of Medicine showed that 32 of the 38, around 84%, could read letters, numbers or words using prosthetic vision after implantation. The system preserves the patient's remaining peripheral vision while adding a small area of artificial central vision.
Science subsequently received a European CE mark covering commercial availability across 30 countries and has begun preparing commercial implants in Germany. The company has also obtained a US Humanitarian Use Device designation while pursuing an American regulatory route.
PRIMA has one big advantage over a general-purpose BCI: everyone knows what successful treatment should accomplish. Doctors can measure visual acuity, patients can tell whether they can read, and the target population is already defined.
That makes vision restoration easier to package clinically than an open-ended promise of controlling computers with thought. Science still has to prove that hospitals can implant PRIMA economically and that reimbursement follows, but it has already moved further down that road than most implanted-neurotech startups.
This is also why “who is winning BCI?” depends heavily on what we mean by winning. Neuralink leads the broad neural-computing race. Science currently has the stronger claim to an approved commercial neural-interface product.
This chart, featured in our neurotechnology market deck, shows why Neuropace is winning in neurotechnology
Is neuromodulation already a better business than brain reading?
Yes, neuromodulation is currently the stronger neurotech business model because companies can build on established medical procedures, regulatory precedents and reimbursement channels.
The funding numbers reflect that. Neuromodulation attracted roughly $791 million in the latest first-half review, more than BCI, and the money was spread across a much larger group of companies. Cognito Therapeutics raised $105 million, Nervonik $52.5 million and Spiro Medical $67 million, while Cala Health, ONWARD Medical and several others also raised meaningful amounts.
The clinical pipeline is equally interesting. Cognito's Spectris system delivers synchronized light and sound stimulation for one hour per day at home to people with Alzheimer's disease. Its pivotal HOPE study enrolled 673 participants across roughly 70 US sites. According to ClinicalTrials.gov, recruitment is complete and the primary study period has finished, although results have not yet been posted. That readout could materially change how seriously investors treat sensory stimulation as therapy.
Flow Neuroscience has already shown that home neuromodulation can survive the FDA's highest-risk PMA process for a depression indication. Cala has shown that a wearable neural-stimulation product can enter reimbursement. Peripheral-nerve stimulation companies are producing commercial exits as well.
The business advantage is simple: neuromodulation can sell a therapeutic outcome without first building an entirely new human-computer interface.
BCI may eventually create a much bigger platform. Today, neuromodulation has the clearer path from clinical evidence to actual revenue.
If you want more recent data on this point, please see our latest neurotechnology market report.
Is consumer neurotech actually becoming a real market?
Consumer neurotech still looks more like a collection of promising products than a proven mass-market category.
Neurable is one of the more credible attempts to change that. Its technology places EEG sensors inside ordinary-looking headphones to estimate mental fatigue, focus and cognitive workload. The company raised $35 million and has expanded beyond its original Master & Dynamic partnership into additional headset projects, including work with gaming brand HyperX.
The product strategy makes sense. Consumers already wear headphones for hours, so Neurable can add neural sensing to an existing behavior rather than asking people to buy a conspicuous EEG headset for its own sake.
The difficulty is proving that people care about the resulting information. Sleep scores, heart rate and step counts became sticky because users can easily understand them and act on them. “Cognitive load” is much harder to turn into a daily habit.
BrainCo shows a different route. The Chinese company raised roughly RMB 2 billion, around $286 million, and has built products spanning EEG, rehabilitation and intelligent prosthetics. Its financing was enormous by neurotech standards, yet Neurofounders found that BrainCo and Temple together accounted for about 95% of all consumer-neurotech funding in the first half of 2026.
That concentration makes the category look bigger than the underlying startup base really is.
We would therefore be cautious about declaring a consumer-neurotech breakout today. The technology is getting much better. A mass consumer habit has yet to appear.
This chart, featured in our neurotechnology market deck, shows annual funding in neurotechnology startups
Is AI genuinely making neurotech products better?
AI is already making neurotech more useful because modern neural interfaces depend heavily on extracting reliable intent from noisy, person-specific biological signals.
This is most obvious in BCIs. Neuralink continually adapts its decoding models as participants use the system. Synchron uses machine learning to translate motor intent into digital commands. Paradromics is building models around high-bandwidth neural data for speech. ABILITY's coming human work will eventually test whether its large data stream can support real-time decoding.
More capable models can help in several ways. They can learn each user's neural patterns, recover useful information when signals shift, combine many channels and convert imperfect neural activity into more stable computer commands. Better software can therefore make the same physical interface more valuable.
Investors have noticed. Merge Labs launched with roughly $252 million of financing and backing from OpenAI while pursuing much earlier-stage approaches involving ultrasound and molecular interfaces. The size of that round says a lot about how strongly some investors now connect AI progress with the future value of brain data.
Still, neural interfaces have physical constraints that machine learning cannot wish away. Electrodes have to remain stable. Scar tissue can change signals. Batteries and wireless links have limits. Surgery has real risks. A therapeutic device still needs clinical evidence.
AI raises the ceiling of what neurotech hardware can do. It does not rescue bad hardware.
Is China catching the US in neurotech faster than people think?
Yes, China is becoming a serious rival in neurotech much faster than the Western BCI conversation usually suggests.
The most visible evidence is capital. BrainCo's roughly $286 million financing became one of the largest BCI-related rounds ever completed outside the US. Chinese industry reporting counted 34 BCI financing events during the first half of 2026, while a more conservative Neurofounders review found 13 rounds of at least RMB 100 million across 12 companies, totaling at least RMB 4.85 billion, around $676 million.
Those companies cover several approaches. NeuroXess is developing implanted interfaces. Gestala raised $21.6 million only two months after launching to work on non-invasive ultrasound BCI. StairMed, Zhiran Medical, Neuracle and others are developing invasive, minimally invasive or non-invasive systems.
China is also building the boring infrastructure that often determines whether a technology scales. Several provinces have started establishing medical-service pricing for BCI procedures, an early step toward reimbursement. National policy calls for major BCI breakthroughs, broader clinical deployment and globally competitive companies before the end of the decade. Two national BCI technical standards have also recently taken effect, covering terminology and shared data formats.
The US still has Neuralink, Synchron, Precision, Paradromics, Science and the deepest individual pools of private BCI capital. China has a different advantage: a growing startup base connected to hospitals, manufacturing companies, local governments and reimbursement experiments.
This is already a two-country technology race, with Europe producing several interesting companies but a much smaller capital pool.
If you want more recent data on this point, please see our latest neurotechnology market report.
This chart, featured in our neurotechnology market deck, compares the main business model options for neurotechnology device platforms
Is regulation still the biggest thing slowing neurotech down?
Regulation matters, but durable clinical benefit, procedure risk and reimbursement are harder bottlenecks for neurotech startups today.
The FDA has already shown several ways a neurotech product can move forward. Flow Neuroscience obtained a full PMA for home depression stimulation. Precision's Layer 7 reached market through a 510(k) clearance for temporary cortical use. Neuralink, Paradromics and other implanted BCI companies can conduct early-feasibility studies under investigational approvals.
Precision's clearance also shows why the word “approved” needs care in neurotech. The cleared Layer 7 product can record and stimulate on the brain's surface for up to 30 days. Precision's permanent wireless BCI still requires additional clinical and regulatory work.
A similar distinction applies to trial authorization. Getting permission to implant one or two people proves that regulators consider a study reasonable enough to conduct. Commercial approval requires a much stronger dataset.
Then comes payment. Cala had to establish Medicare access after receiving device authorization. Flow now has to convince physicians and patients to use prescription home stimulation. Science needs European hospitals and payers to support PRIMA implantation. Even a brilliant BCI will struggle commercially if hospitals lose money every time they implant it.
The FDA can certainly slow a company down. For the strongest neurotech startups, though, the tougher question now is whether a technically impressive device produces enough real-world benefit to justify its cost and medical complexity.
What do recent neurotech exits tell us about startup valuations?
Recent neurotech deals suggest that venture investors are paying huge premiums for future platforms while strategic buyers remain much more disciplined about mature medical-device economics.
Boston Scientific completed its acquisition of Nalu Medical in early 2026 after investing in the company since 2017. The company paid roughly $517 million in cash for the stake it did not already own. Nalu makes a miniature peripheral-nerve stimulation system for chronic pain and fits directly inside Boston Scientific's existing neuromodulation business.
Nevro gives us a much harsher comparison. Globus Medical acquired the spinal-cord stimulation company for about $250 million. Nevro had produced roughly $408 million to $409 million of revenue during the previous year.
That means a real neurostimulation company with FDA-approved products and more than $400 million in annual sales changed hands at only about 0.6 times revenue.
Compare that with frontier BCI. Neuralink raised $650 million in a single private round while remaining pre-commercial. Merge Labs raised around $252 million at an extremely early technical stage. Science raised $230 million before the commercial launch of PRIMA.
Investors are clearly valuing the possibility that these companies create entirely new platforms rather than applying conventional medtech multiples.
Nevro is a useful warning. Once neurotech becomes a normal medical-device business, revenue growth, gross margins, competition, reimbursement and operating costs start mattering far more than how futuristic the technology sounds.
This chart, featured in our neurotechnology market deck, breaks down revenue by customer segment in the neurotechnology market
So what does the neurotech startup landscape look like today?
The neurotech startup landscape today is much stronger than it was a few years ago, but the commercial winners are emerging in a very different order from the companies generating the most hype.
Implanted BCI has made the biggest technical jump. Multiple companies now have human data, several interface architectures are being tested, and patients are using neural implants to control computers or assistive devices. Neuralink currently leads the broad platform race, while Synchron, Precision, Paradromics and newer entrants such as ABILITY are testing very different ways of balancing bandwidth against surgical complexity.
The first serious commercial businesses are appearing elsewhere. Science has started the European launch of a retinal neuroprosthesis. Flow can commercially distribute an FDA-approved home depression treatment. Cala has reimbursement. Epitel is raising money to expand an already cleared wireless EEG platform. Neuromodulation, overall, is attracting more broadly distributed capital than BCI.
Consumer neurotech remains the weakest part of the story. Better EEG hardware and smarter algorithms have produced more usable products, but we still do not see a neural equivalent of the smartwatch: something tens of millions of ordinary consumers clearly want to use every day.
China has also changed the competitive map. Large financing rounds, dozens of startups, new technical standards and early reimbursement infrastructure mean the US can no longer be treated as the only serious neurotech ecosystem.
Neurotech has now moved into a real commercialization cycle. The important shift is visible in hospitals, regulatory approvals, reimbursement decisions, human implants and commercial launches rather than in another futuristic demonstration.
The companies most likely to break out first are therefore the ones solving a narrow, expensive neurological problem extremely well. Restoring vision, reducing tremor, monitoring seizures, treating depression or giving a paralyzed patient reliable computer control all have clearer economic value than a vague promise to “connect the brain to AI.”
General-purpose neural computing may eventually become the largest prize in the sector. For now, medical neurotech is where the startup landscape is becoming a real market.
If you want more recent data on this point, please see our latest neurotechnology market report.
OUR METHODOLOGY
This analysis looks at the neurotech startup landscape through funding, human clinical use, regulatory progress, commercial launches, reimbursement, technical architecture, geographic development and completed transactions. We define neurotech narrowly as products that directly read, measure, stimulate or interface with the nervous system, rather than including every mental-health, drug or AI company that works around neurological problems.
We treated funding and commercial maturity as separate questions. The funding section uses Neurofounders’ August 9, 2026 H1 review, which reports roughly $2.64 billion across 81 financing events among 363 companies on its startup map. We looked at the distribution underneath the headline total as well, because a small number of very large rounds account for most of the disclosed capital.
For BCI progress, we separated technical performance from clinical scale and market readiness. Human implants, electrode counts and cursor-control results show that the interfaces can work, but they do not by themselves prove long-term reliability, repeatable surgery, reimbursement or a scalable business. We also avoided forcing Neuralink, Synchron, Precision Neuroscience, Paradromics and ABILITY Neurotech into a single hardware ranking because they are optimizing for different trade-offs.
For commercial maturity, we gave more weight to regulatory decisions, reimbursement, provider adoption and actual launch activity than to product demonstrations. That is why companies such as Science Corporation, Flow Neuroscience, Cala Health, Epitel and Precision can rank ahead commercially even when frontier BCI companies attract more attention and capital. Completed acquisitions such as Nalu Medical and Nevro were used as a reality check on how strategic buyers value established neuromodulation businesses once they are judged on ordinary medtech economics.
Key sources include Neurofounders’ H1 2026 funding review, Neuralink’s Series E announcement and company updates, Precision Neuroscience’s Layer 7 clearance announcement, the FDA Layer 7-T 510(k) summary, Synchron’s company news, Paradromics’ company updates, the FDA approval record for Flow Neuroscience’s FL-100, ClinicalTrials.gov for Cognito Therapeutics’ HOPE study, the New England Journal of Medicine PRIMA study, Financial Times reporting on PRIMA’s European launch, Boston Scientific’s 2025 annual report, Globus Medical’s Nevro acquisition filing, Hangzhou municipal reporting on BrainCo’s financing, and WIRED on Merge Labs’ financing and OpenAI involvement.
This chart, featured in our neurotechnology market deck, shows how brain sensing wearable technology has evolved over time
Related blog posts
- How strong is fundraising in the neurotechnology market right now?
